Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | FPR2 | P25090 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410703 | 0.89 | HDAC3 (0.50) | EPHX2MEN1KMT2AHDAC3HDAC8 | |
| SCHEMBL2406688 | 0.86 | RAB9A (0.47) | MEN1KMT2AHDAC3MAPTHTT | |
| SCHEMBL2409353 | 0.86 | SMN1; SMN2 (0.58) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL2405849 | 0.85 | ALDH1A1 (0.54) | EPHX2FPR2HDAC3HDAC8HDAC6 | |
| SCHEMBL12271399 | 0.85 | RXFP1 (0.44) | MEN1KMT2AHDAC3MAPTRAB9A | |
| SCHEMBL12271271 | 0.84 | HSD17B10 (0.56) | EPHX2HDAC3HDAC8HDAC6HTT | |
| SCHEMBL2406913 | 0.83 | KDR (0.43) | MEN1KMT2AHDAC3HDAC6TRPV1 | |
| SCHEMBL2406864 | 0.83 | KDR (0.56) | HDAC3HDAC8HDAC6TRPV1MAPT | |
| SCHEMBL2409476 | 0.82 | CA12 (0.43) | TRPV1MAPT | |
| SCHEMBL12271534 | 0.82 | ANPEP (0.53) | FPR2MEN1KMT2AHDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546588-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-9227951-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227951-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8546588-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2011106627-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | EPHX2 1561/4885FPR2 933/4885MEN1 3939/4885 |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | EPHX2 1561/4885FPR2 933/4885MEN1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.